Novel agents interfering with unique biologic features, that is, B cell receptor (BCR) downstream signaling and BCL2, are being rapidly introduced in clinical practice, representing a new scenario of mechanism-driven treatment of CLL, producing rapid and durable responses in relapsed/refractory CLL 18,19. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.